Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock Holdings Increased by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC boosted its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 3.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 932,231 shares of the company's stock after purchasing an additional 32,041 shares during the quarter. ArrowMark Colorado Holdings LLC owned about 0.92% of Dyne Therapeutics worth $21,963,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Barclays PLC raised its position in Dyne Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 207,309 shares of the company's stock worth $7,446,000 after acquiring an additional 128,246 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Dyne Therapeutics by 4.3% in the third quarter. JPMorgan Chase & Co. now owns 101,750 shares of the company's stock valued at $3,655,000 after purchasing an additional 4,236 shares during the last quarter. KBC Group NV increased its stake in shares of Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company's stock worth $74,000 after purchasing an additional 978 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Dyne Therapeutics by 11.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company's stock worth $508,000 after purchasing an additional 2,265 shares during the last quarter. Finally, abrdn plc purchased a new stake in Dyne Therapeutics in the 4th quarter valued at approximately $608,000. Institutional investors and hedge funds own 96.68% of the company's stock.

Dyne Therapeutics Trading Down 14.9 %

NASDAQ:DYN traded down $1.76 during midday trading on Tuesday, hitting $10.07. 6,130,495 shares of the stock were exchanged, compared to its average volume of 1,581,895. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -2.83 and a beta of 1.19. Dyne Therapeutics, Inc. has a one year low of $6.36 and a one year high of $47.45. The business has a 50-day moving average price of $10.54 and a two-hundred day moving average price of $18.59.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.04. Sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares of the company's stock, valued at $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last three months, insiders sold 6,237 shares of company stock valued at $77,760. 20.77% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DYN. Piper Sandler dropped their target price on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Guggenheim restated a "buy" rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Scotiabank started coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price objective for the company. Chardan Capital reissued a "buy" rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 17th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research note on Friday, March 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $47.46.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.